{
  "title": "New Patient Outcome Assessed in Psoriasis Biologic Trial - Medscape",
  "url": "https://www.medscape.com/viewarticle/move-toward-assessing-well-being-psoriasis-biologic-2025a1000rgw",
  "summary": [
    {
      "type": "bullet",
      "text": "**Patient-Centered Outcome as Primary Endpoint:** The POSITIVE trial uses a patient-reported outcome, specifically the WHO-5 Well-Being Index, as the primary endpoint for evaluating recovery two years after initiating therapy with tildrakizumab in plaque psoriasis patients. This shift towards holistic care measures mental and physical recovery alongside disease control."
    },
    {
      "type": "bullet",
      "text": "**Early Improvement in Mental Health:** Within 16 weeks of treatment initiation, patients showed a significant improvement in psychological well-being (WHO-5 score) from a baseline comparable to those with breast cancer or diabetes, indicating early positive effects on mental health despite similar skin clearance levels."
    },
    {
      "type": "bullet",
      "text": "**Complex Relationship Between Physical and Mental Recovery:** Despite achieving clear skin, some patients experienced delays in improving their mental well-being as measured by the WHO-5 index. This suggests a complex interplay between physical disease control and mental recovery, potentially influenced by persistent anxiety about potential relapse."
    },
    {
      "type": "bullet",
      "text": "**Importance of Partner Well-being:** The trial's secondary analysis highlighted that while patients showed quicker improvement in psychological well-being compared to their partners, indicating some level of concern or slower recovery among partners due to perceived instability of the treatment effect. This underscores the importance of considering partner and family well-being as part of patient-centered healthcare approaches."
    },
    {
      "type": "bullet",
      "text": "**Shift Towards Holistic Care in Dermatology:** The study supports a broader initiative by the World Health Organization (WHO) towards evaluating therapeutic benefits more holistically in chronic diseases, moving beyond mere disease control to include quality of life improvements, thus redefining value-based care in dermatology and potentially other fields."
    }
  ],
  "model": "granite4:tiny-h"
}